NCT04573309View on ClinicalTrials.gov

Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 7, 2020

Primary Completion Date

June 7, 2022

Study Completion Date

June 7, 2022

Conditions
Wilson Disease
Interventions
DRUG

ALXN1840

Administered orally as tablets.

Trial Locations (3)

1010

Research Site, Grafton

06510

Research Site, New Haven

SE1 1YR

Research Site, London

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY